GLAXONSEGlaxoSmithKline Pharmaceuticals Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 6 Nov, 2025 · 16:34 IST

GSK Pharma Q2 results: profit up, revenue dips; Rs 1.74 cr solar investment

Revenue DeclineExceptional ItemEbitda Margin CompressionResults View source PDFExplain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.3%Reaction day
₹2578.00
prior close
₹2605.50
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.5%-0.2% vs market
Pharmaceuticals peers, median of 156sector-0.1%+0.3% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.2
10m
-1.9
15m
-2.3
30m
-2.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.3+0.5-0.2-0.1+0.3
Next day
-1.5+0.9-2.4-0.7-0.8
2d
-3.9+1.4-5.3-0.9-3.0
3d
-3.0+2.1-5.1+0.1-3.1
4d
-3.2+1.8-5.0+0.2-3.4
5d
-3.9+1.9-5.8+0.0-3.9
1w
-3.4+1.9-5.3-0.3-3.1
15d
-0.3+2.2-2.5-1.7+1.4
1m
-1.7-0.4-1.3-5.4+3.6
2m
-4.8+3.1-7.9-2.8-2.0
3m
-2.4+1.6-4.0-7.4+4.9
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q2 revenue fell to Rs 973.6 cr from about Rs 1,000 cr YoY. Net profit rose to Rs 255 cr from Rs 248.7 cr, aided by Rs 2.6 cr exceptional gain from sale of surplus residential properties. EBITDA margins compressed. H1 consolidated PAT at Rs 462.5 cr vs Rs 434.8 cr. Board approved Rs 1.74 cr investment in a solar power SPV for the Nashik plant. Deloitte Haskins and Sells LLP issued an unmodified limited review.

Likely market impact

Soft revenue with margin pressure, but profit supported by one-time gains. Small solar capex is a positive ESG step. Overall results are largely flat.